M. Hassan-Zahraee

发表

Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II1

B. Walker, C. Brander, A. Trocha, 2004, The Journal of Immunology.

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

S. Schreiber, R. Clare, G. D'Haens, 2017, Gut.

Blockade of cytosolic phospholipase A2α prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses

M. Leach, Takao Shimizu, J. D. Clark, 2008, Journal of Neuroimmunology.

Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1.

W. Reinisch, K. Hung, M. Hassan-Zahraee, 2018, Journal of Crohn's & colitis.

Immune cell entry to the CNS--a focus for immunoregulation of EAE.

T. Owens, E. Tran, M. Hassan-Zahraee, 1998, Research in immunology.

Rapid synthesis of IFN-gamma by T cells in skin may play a pivotal role in the human skin immune system.

J. Gordon, M. Hassan-Zahraee, J. Wu, 1998, International immunology.

Cytosolic Phospholipase A2α Blockade Abrogates Disease during the Tissue-Damage Effector Phase of Experimental Autoimmune Encephalomyelitis by Its Action on APCs

V. Kuchroo, M. Leach, J. D. Clark, 2011, The Journal of Immunology.

This information is current as Encephalomyelitis by Its Action on APCs Effector Phase of Experimental Autoimmune Abrogates Disease during the Tissue-Damage Blockade α 2 Cytosolic Phospholipase

V. Kuchroo, M. Leach, J. D. Clark, 2011 .

Superantigen presenting capacity of human astrocytes

R. Sékaly, J. Antel, T. Owens, 2000, Journal of Neuroimmunology.

Bone marrow-derived versus parenchymal sources of inducible nitric oxide synthase in experimental autoimmune encephalomyelitis

T. Owens, S. Zehntner, E. Tran, 2004, Journal of Neuroimmunology.

Quantification of Th1 and Th17 Cells with Intracellular Staining Following PMA/Ionomycin Stimulation

M. Hassan-Zahraee, Fridrik J Karlsson, 2015, Current protocols in cytometry.

Elevated interferon-gamma in CNS inflammatory disease: a potential complication for bone marrow reconstitution in MS

T. Owens, E. Tran, M. Hassan-Zahraee, 2000, Journal of Neuroimmunology.

901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study

S. Vermeire, J. S. Kim, W. Sandborn, 2015 .

The pathogenesis of encephalitis

B. Finsen, T. Owens, S. Fournier, 2001 .

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study

S. Vermeire, R. Ransohoff, R. Clare, 2017, Journal of Crohn's & colitis.

A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis

E. Peeva, C. Hyde, J. Krueger, 2022, Scientific Reports.

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study [102/120 characters including spaces].

E. Peeva, S. Danese, K. Hung, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers

Shanrong Zhao, Baohong Zhang, D. Ziemek, 2019, Journal of Crohn's & Colitis.

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

S. Vermeire, J. S. Kim, R. Clare, 2017, The Lancet.

The delayed hypersensitivity response and host resistance in surgical patients. 20 years later.

J. Meakins, N. Christou, M. Hassan-Zahraee, 1995 .

Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis

Zhan Ye, M. Baniecki, S. Danese, 2021, Inflammatory bowel diseases.

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study

T. Hibi, R. Clare, M. Saruta, 2020, Intestinal research.

First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects

K. Hung, C. Banfield, I. Bhattacharya, 2019, British journal of clinical pharmacology.

The Delayed Hypersensitivity Response and Host Resistance in Surgical Patients: 20 Years Later

J. Meakins, N. Christou, M. Hassan-Zahraee, 1995, Annals of surgery.

Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.

E. Peeva, W. Sandborn, S. Danese, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA study

W. Reinisch, J. Claus, A. Banerjee, 2015 .

Blockade of cytosolic phospholipase A2α prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses

M. Leach, Takao Shimizu, J. D. Clark, 2008, Journal of Neuroimmunology.

Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn’s Disease

Steven W. Martin, R. Clare, Baohong Zhang, 2017, Journal of Crohn's & colitis.